Abstract
Cancer represents a significant epidemiological and economic challenge worldwide. Managing this group of diseases is marked by a shortage of curative and low-toxicity therapeutic approaches, especially when patients are in advanced stages. In particular, there is a clear lack of drugs capable of inhibiting neoplastic stem cells (NSCs) - one of the primary factors responsible for therapeut…